and contiguous, the opportunity to successfully and consistently ablate renal nerve tissue is enhanced. BACKGROUND Catheter-based renal artery denervation therapy is under evaluation as a therapeutic option in patients with resistant hypertension. Despite promising data from initial studies, the lack of a clear treatment effect from the SYMPLICITY HTN 3 trial raised concerns around the efficacy of renal denervation. Subsequent subanalysis has suggested significant treatment effects if patients receive more and circumferential lesions, suggesting that multi-electrode renal denervation systems may reduce the risk of an inadequate renal denervation procedure. In order to gain insights from a large patient dataset, we investigated the safety and performance of the EnligHTNÔ Renal Denervation System (St. Jude Medical) in patients with drug-resistant hypertension using poled data from all trials performed to date. This is the first report of pooled data from the EnligHTN I, II and III trials.
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METHODS
The EnligHTN renal artery ablation catheter has 4 electrodes attached on a basket mounted at the tip of the catheter. We analysed data from the EnligHTN I, III and III trials which met the following criteria: 18-80 years of age, an office systolic BP ! 160 mmHg, on three or more antihypertensive agents (including a diuretic), and renal artery diameter ! 4mm and length ! 20mm. All trials used the same renal artery ablation catheter, but in the EnligHTN I and early phase of the EnligHTN II trials, sequential delivery of radiofrequency energy was performed, whereas with the later phase of the EnligHTN II trial and the EnligHTN III trial the next generation simultaneous delivery of radiofrequency was performed.
RESULTS To date 202 patients met this criteria from these 3 studies, with 6 month follow up data available (EI n¼46, EII n¼119, EIII n¼37). Mean age for the dataset was 62 yr.s with mean office systolic BP at baseline of 179mmHg and at 6 months of 158mmHg. Therefore a 6 month reduction in office systolic BP of 21mmHg was noted (p<0.05). Mean 24 hr systolic ABP at baseline was 156mmHg and at 6 months was 148mmHg. This 8mmHg drop was statistically significant (p<0.0001). With regards BP reduction within this dataset, baseline systolic office and 24 hour ambulatory BP values at baseline were predictors of the level of BP reduction. Enrollment within the first in human trials (EI&III) had larger observed reductions in BP. Complete safety analysis including renal function and adverse events will be included in the presentation.
CONCLUSIONS Pooled data from the complete EnligHTN clinical trial dataset meeting traditional study definitions of resistant hypertension confirm the efficacy and safety of the EnligHTN multi-electrode system for renal artery denervation. Future randomised controlled trials in the patient population with next generation multi-electrode renal denervation systems are warranted. 28-4.80] ). Patients with more predictors had a higher incidence of death after revascularization. (Figure) CONCLUSIONS Non-ambulatory status, emaciation, and low albumin level were independently associated with mortality after revascularization in octogenarian patients with CLI. Risk stratification by these factors might inform revascularization strategy decision.
